Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has
increased over the last few decades. It derives from follicular thyroid cells. Generally …

Differentiated thyroid cancer, which includes papillary and follicular histologies, is a common
malignancy and is increasing in incidence. It carries a favorable prognosis compared to …

Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine
and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular …

Thyroid cancer can be largely classified as well-differentiated, poorly differentiated,
medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and …

Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including
gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity …

Thyroid cancer is the most common endocrine malignancy, although representing fewer
than 1% of all human tumors. Differentiated thyroid carcinoma (DTC) includes the papillary …

Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally
an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating …

Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

For patients with metastatic differentiated thyroid carcinoma that progresses despite
standard therapies, systemic cytotoxic chemotherapy has traditionally been a limited option …